Arcadis N.V. (ARCAD)
Euronext Amsterdam · Netherlands · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 43.90 |
|---|---|
| 52-week range | 25.88 – 51.25 |
| Return, 1 month / 3 months | +4.6% / +5.5% |
| Return, 1 year / 3 years | −10.8% / +22.2% |
| Trend | Uptrend |
| RSI (14) | 66 |
| Volatility (1 year) | 38.0% |
| Worst drawdown (1 year) | -36.9% |
| Average daily value traded | 6.20M EUR |
| Dividend yield | 2.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Arcadis is a design, engineering and consultancy company based in the Netherlands. It advises and works on projects in infrastructure, water, the environment and buildings, serving governments, municipalities and private businesses around the world. Its people plan, design and manage construction and environmental work, and the firm also offers consultancy on sustainability and asset management. Arcadis operates through a network of offices in many countries, drawing on engineers, scientists and consultants to deliver projects for its clients.
Arcadis N.V. trades under the code ARCAD on the Euronext Amsterdam in Netherlands, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Arcadis N.V. (ARCAD) trades on the Euronext Amsterdam in Netherlands. It last closed at EUR 43.90 on 27 October 2026.
Its price-based Market X-Ray is 57 out of 100 (a fair price profile), ranking 49 of 109 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 10.8% and over the last three months it rose 5.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Amsterdam
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 81 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 21.9% | ||
| From 52-week high | -13.5% | ||
| Momentum | 62 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 5.5% | ||
| 6-month return | 42.4% | ||
| 12-month return, skipping the last month | -14.7% | ||
| Stability (higher is calmer) | 29 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 38.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -36.9% | ||
| Liquidity | 67 · Fair | Moderate trading activity. | |
| Average daily value traded | 6.20M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 38 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.4% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +7.2% |
|---|---|
| 1 month | +4.6% |
| 3 months | +5.5% |
| 6 months | +42.4% |
| 1 year | −10.8% |
| 3 years | +22.2% |
| 5 years | +7.0% |
Signals
| 50-day / 200-day average | 42.52 / 36.01 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.96 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 22 May 2026 | EUR 1.0500 |
| 20 May 2025 | EUR 1.0000 |
| 10 May 2024 | EUR 0.8500 |
| 16 May 2023 | EUR 0.7400 |
| 16 May 2022 | EUR 1.3000 |
| 3 May 2021 | EUR 0.6000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Amsterdam; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.